Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma

Journal of Veterinary Internal Medicine

Volumn 21, Issue 6, 2007, Pages 1347-1354

  Sorenmo, Karin ^a,b,j   Samluk, Marissa ^a,c,f   Clifford, Craig ^a,d   Baez, Jennifer ^a,e   Barrett, Jeffrey S ^g   Poppenga, Robert ^a,h   Overley, Beth ^a   Skorupski, Katherine ^a,h   Oberthaler, Karen ^a,i   Van Winkle, Tom ^a   Seiler, Gabriela ^a   Shofer, Frances ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Laboratories of Biochemistry   (United States)

^c Veterinary Referral Center of Colorado   (United States)

^d RED BANK VETERINARY HOSPITAL   (United States)

^e CARES (Center for Animal Referral and Emergency Services)   (United States)

^f Veterinary Pet Insurance   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Florida Veterinary Specialists   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Chemotherapy; Intraperitoneal administration; Pharmacokinetics; Splenic malignant endothelioma

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ANGIOSARCOMA; ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; SPLEEN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOXORUBICIN; HEMANGIOSARCOMA; POLYETHYLENE GLYCOLS; SPLENIC NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 37349073080     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/06-214.1     Document Type: Article

References (34)

1. Prymak C, McKee LJ, Goldschmidt MH, et al. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc 1988;193:706-712.
2. Johnson KA, Powers BE, Withrow SJ, et al. Splenomegaly in dogs: Predictors of neoplasia and survival after splenectomy. J Vet Intern Med 1989;3:160-166.
3. Wood CA, Moore AS, Gliatto JG, et al. Prognosis for dogs with stage I and II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc 1998;34:417-421.
4. Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: Retrospective analysis of 104 cases. J Am Vet Med Assoc 1985;186:56-58.
5. Hammer AS, Couto GC, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160-166.
6. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370-376.
7. Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379-384.
8. Sorenmo K, Duda L, Barber L, et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 2000;14:395-398.
9. Sorenmo K, Baez J, Clifford C, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 2004;18:209-213.
10. Pearson GR, Head KW. Malignant haemangioendothelioma (angiosarcoma) in the dog. J Small Anim Pract 1976;17:737-745.
11. Moulton JE. Tumors in Domestic Animals, 2nd ed. Berkeley: University of California Press, 1978:35-36.
12. Oksanen A. Hemangiosarcoma in dogs. J Comp Path 1978;88:585-595.
13. Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med 2000; 14:479-485.
14. Moore AS, Kirk C, Cardona A. Intracavitary cisplatin chemotherapy experience with six dogs. J Vet Intern Med 1991;5:227-231.
15. Charney SC, Bergman PJ, McKnight J, et al. Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002). Vet Comp Oncol 2005;3:171-181.
16. Sadzuka Y, Hirota S, Takasi S. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett 2000;116:51-59.
17. Gabizon A, Martin F. Polyethylene glycol coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors., Drugs 1997;54:15-21.
18. Gabizon A, Catane R. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1997;54:987-992.
19. Gabizon A, Editorial: Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet. Clin Cancer Res 2001;7:223-225.
20. Vaage J, Donovan D, Mayhew E, et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993;72:3672-3675.
21. Vail D, Kravis L, Cooley J, et al. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol 1997;39:410-416.
22. Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567-1571.
23. De Bruijn P, Verweij J, Loos WJ, et al. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999;266:216-221.
24. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated liposomes containing polyethylene glycol-derivatized phospholipids: Pharmacokinetic studies in rats and dogs. Pharm Res 1993;10:703-708.
25. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12(Suppl 4):1-6.
26. Dedrick RL, Flesser MF. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480-487.
27. Alberts Ds, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
28. Barakat RR, Fennelly D, Pizzuto F, et al. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: Impact of retroperitoneal nodal disease. Eur J Gynaecol Oncol 1997;18:161-163.
29. Speyer JL, Sugarbaker PH, Collins JM, et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981;41:1916-1922.
30. Makhija S, Sabbatinu P, Barakat RR. Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Curr Opin Obstet Gynecol 1999;11:23-27.
31. Penna C, Nordlinger B. Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Eur J Cancer 1996;32:1117-1122.
32. Parker RJ, Priester ER, Sieber SM. Effect of route administration and liposome entrapment on the metabolism and disposition of Adriamycin in the rat. Drug Metab Dispos 1982;10:499-504.
33. Parker RJ, Priester ER, Sieber SM. Comparison of lymphatic uptake, metabolism, excretion and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats. Drug Metab Dispos 1982;10:40-46.
34. Oussoren C, Zuidema J, Crommelin DJ, et al. Lymphatic uptake and biodistribution of liposomes after SC injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochem Biophys Acta 1997;1328:261-272.